"""
Question: 1101 

Evidence: We used population-based HIV partner services data to evaluate trends in prior or ineffective PrEP use and reasons for stopping PrEP among MSM with newly diagnosed HIV in King County, WA, from 2013 to 2021. These data were entered into an electronic database and analyzed for this study.

Rationale: The paper analyzes partner services data collected and analyzed specifically for this study period (2013–2021), indicating it presents original, previously unpublished data rather than a review or re-analysis of publicly available datasets.

Answer: Yes
"""

"""
Question: 1102 

Evidence: HIV genotype data were available for 15 (79%) of the 19 men who reported being on PrEP at the time of diagnosis. Wild-type virus was identified in 7 cases (47%). The remaining 8 cases (53%) had 1 or more nucleoside reverse transcriptase inhibitor resistance mutations.

Rationale: The paper reports summarized genotypic results and specific mutations but does not provide nucleotide or amino acid sequences or accession numbers, hence it does not report HIV sequences.

Answer: No
"""

"""
Question: 1103 

Evidence: We used population-based HIV partner services data to evaluate trends in prior or ineffective PrEP use and reasons for stopping PrEP. These activities were conducted as part of a public health PrEP program evaluation and therefore were not considered human subjects research.

Rationale: The study is an observational public health evaluation without laboratory experimental methods; there is no mention of laboratory in vitro passage experiments.

Answer: No
"""

"""
Question: 1104 

Evidence: HIV genotype data were available for 15 (79%) of the 19 men who reported being on PrEP at the time of diagnosis. The remaining 8 cases (53%) had 1 or more nucleoside reverse transcriptase inhibitor resistance mutations.

Rationale: The paper reports genotypic resistance results only and does not describe any phenotypic susceptibility testing or in vitro drug susceptibility assays.

Answer: No
"""

"""
Question: 2101 

Evidence: HIV genotype data were available for 15 (79%) of the 19 men who reported being on PrEP at the time of diagnosis. High-level tenofovir resistance was detected for 3 cases.

Rationale: Although genotypic results are reported, there are no GenBank accession numbers provided anywhere in the text.

Answer: No
"""

"""
Question: 2102 

Evidence: HIV genotype data were available for 15 (79%) of the 19 men who reported being on PrEP at the time of diagnosis. High-level tenofovir resistance was detected for 3 cases.

Rationale: The paper does not provide any GenBank accession numbers for any sequenced isolates, including clinical isolates.

Answer: No
"""

"""
Question: 2103 

Evidence: HIV genotype data were available for 15 (79%) of the 19 men who reported being on PrEP at the time of diagnosis. High-level tenofovir resistance was detected for 3 cases.

Rationale: No GenBank accession numbers are reported in the paper; therefore none can be listed.

Answer: NA
"""

"""
Question: 2202 

Evidence: The remaining 8 cases (53%) had 1 or more nucleoside reverse transcriptase inhibitor resistance mutations, including 4 cases of an isolated M184V and 1 case of M41L/M184V/T215E. High-level tenofovir resistance was detected for 3 cases.

Rationale: Mutations are summarized in aggregate and not listed per individual isolate; there is no table or list mapping individual sequences to their specific mutations.

Answer: No
"""

"""
Question: 2301 

Evidence: HIV genotype data were available for 15 (79%) of the 19 men who reported being on PrEP at the time of diagnosis. We used population-based HIV partner services data to evaluate trends in prior or ineffective PrEP use and reasons for stopping PrEP among MSM with newly diagnosed HIV.

Rationale: The paper refers generically to “HIV” and does not specify HIV-1 or HIV-2 species; thus the species cannot be determined from the provided text.

Answer: NA
"""

"""
Question: 2302 

Evidence: HIV genotype data were available for 15 (79%) of the 19 men who reported being on PrEP at the time of diagnosis. High-level tenofovir resistance was detected for 3 cases.

Rationale: No HIV subtype information is reported in the text.

Answer: NA
"""

"""
Question: 2303 

Evidence: The remaining 8 cases (53%) had 1 or more nucleoside reverse transcriptase inhibitor resistance mutations, including 4 cases of an isolated M184V and 1 case of M41L/M184V/T215E. High-level tenofovir resistance was detected for 3 cases: 1 with K65R/M184V and 2 with A62V/K65R/M184V mutations.

Rationale: The reported mutations (M184V, M41L, T215E, K65R, A62V) are in reverse transcriptase, indicating sequencing of the reverse transcriptase region of pol.

Answer: Reverse transcriptase (pol)
"""

"""
Question: 2304 

Evidence: The remaining 8 cases (53%) had 1 or more nucleoside reverse transcriptase inhibitor resistance mutations, including 4 cases of an isolated M184V and 1 case of M41L/M184V/T215E. High-level tenofovir resistance was detected for 3 cases: 1 with K65R/M184V and 2 with A62V/K65R/M184V mutations.

Rationale: Reporting specific reverse transcriptase mutations constitutes results from the pol gene region.

Answer: Yes
"""

"""
Question: 2401 

Evidence: We used population-based HIV partner services data to evaluate trends in prior or ineffective PrEP use and reasons for stopping PrEP among MSM with newly diagnosed HIV in King County, WA, from 2013 to 2021. FIGURE 1.: Number of new HIV diagnoses among MSM in King County, WA, by PrEP use status, 2013–2021.

Rationale: All subjects and the genotyped subset were from King County, Washington, USA.

Answer: King County, Washington, USA
"""

"""
Question: 2402 

Evidence: Data span from October 2013 to August 2021. The proportion of men who ever used PrEP before HIV diagnosis increased from 2.3% in 2014 to 26.6% in 2020 through August of 2021.

Rationale: The genotyped cases are within the study period of 2013–2021; no narrower dates for sequencing are provided.

Answer: 2013–2021
"""

"""
Question: 2502 

Evidence: HIV genotype data were available for 15 (79%) of the 19 men who reported being on PrEP at the time of diagnosis. Information about patterns of PrEP use (eg, intermittent or event-driven) was not routinely collected.

Rationale: The paper does not describe the sequencing methodology (e.g., Sanger vs NGS); therefore it cannot be determined.

Answer: NA
"""

"""
Question: 2503 

Evidence: HIV genotype data were available for 15 (79%) of the 19 men who reported being on PrEP at the time of diagnosis. Information about patterns of PrEP use (eg, intermittent or event-driven) was not routinely collected.

Rationale: The sequencing platform or technology is not specified.

Answer: NA
"""

"""
Question: 2504 

Evidence: HIV genotype data were available for 15 (79%) of the 19 men who reported being on PrEP at the time of diagnosis. Wild-type virus was identified in 7 cases (47%).

Rationale: The paper provides no details indicating that samples were cloned prior to sequencing.

Answer: NA
"""

"""
Question: 2505 

Evidence: HIV genotype data were available for 15 (79%) of the 19 men who reported being on PrEP at the time of diagnosis. Wild-type virus was identified in 7 cases (47%).

Rationale: There is no mention of single-genome sequencing in the methods or results.

Answer: NA
"""

"""
Question: 2506 

Evidence: HIV genotype data were available for 15 (79%) of the 19 men who reported being on PrEP at the time of diagnosis. Wild-type virus was identified in 7 cases (47%).

Rationale: The paper does not describe molecular cloning.

Answer: NA
"""

"""
Question: 2601 

Evidence: HIV genotype data were available for 15 (79%) of the 19 men who reported being on PrEP at the time of diagnosis. Partner services staff were able to confirm that 18 (95%) of these men, including those with detectable resistance mutations, were successfully linked to HIV care and initiated on active antiretroviral therapy.

Rationale: The sample source for sequencing (e.g., plasma RNA) is not stated.

Answer: NA
"""

"""
Question: 2602 

Evidence: HIV genotype data were available for 15 (79%) of the 19 men who reported being on PrEP at the time of diagnosis. Partner services staff were able to confirm that 18 (95%) of these men were successfully linked to HIV care and initiated on active antiretroviral therapy.

Rationale: The paper does not state that PBMC DNA sequencing was performed.

Answer: NA
"""

"""
Question: 2603 

Evidence: HIV genotype data were available for 15 (79%) of the 19 men who reported being on PrEP at the time of diagnosis. Wild-type virus was identified in 7 cases (47%).

Rationale: The paper does not specify how many genotypes were from plasma; thus the number undergoing plasma virus sequencing cannot be determined.

Answer: NA
"""

"""
Question: 2604 

Evidence: HIV genotype data were available for 15 (79%) of the 19 men who reported being on PrEP at the time of diagnosis. Wild-type virus was identified in 7 cases (47%).

Rationale: The paper does not specify PBMC-derived sequencing counts.

Answer: NA
"""

"""
Question: 2605 

Evidence: Nineteen men were on PrEP at the time of HIV diagnosis. Partner services staff were able to confirm that 18 (95%) of these men were successfully linked to HIV care and initiated on active antiretroviral therapy.

Rationale: Although newly diagnosed individuals are typically viremic, the paper does not explicitly state viral replication status at the time of sequencing.

Answer: NA
"""

"""
Question: 2606 

Evidence: HIV genotype data were available for 15 (79%) of the 19 men who reported being on PrEP at the time of diagnosis. The study does not describe laboratory methods beyond reporting mutation results.

Rationale: There is no indication that sequencing was performed from proviral DNA reservoirs.

Answer: NA
"""

"""
Question: 2701 

Evidence: The current analysis includes data from all cases of newly diagnosed and reported HIV in adult MSM in King County from October 2013 to August 2021. The median age was 32 years (interquartile range [IQR]: 26–41).

Rationale: The study population consists of adults; infants/children are not included.

Answer: No
"""

"""
Question: 2702 

Evidence: These activities were conducted as part of a public health PrEP program evaluation and therefore were not considered human subjects research. We used population-based HIV partner services data to evaluate trends.

Rationale: There is no mention of clinical trial participation; the evaluation was a public health program assessment, not a clinical trial.

Answer: NA
"""

"""
Question: 2703 

Evidence: These activities were conducted as part of a public health PrEP program evaluation and therefore were not considered human subjects research. We used population-based HIV partner services data.

Rationale: Because no clinical trial is described, it cannot be stated that all individuals were in a clinical trial.

Answer: NA
"""

"""
Question: 3101 

Evidence: HIV genotype data were available for 15 (79%) of the 19 men who reported being on PrEP at the time of diagnosis. Wild-type virus was identified in 7 cases (47%).

Rationale: The number of individuals with sequencing (genotype) results is explicitly given as 15.

Answer: 15
"""

"""
Question: 3102 

Evidence: HIV genotype data were available for 15 (79%) of the 19 men who reported being on PrEP at the time of diagnosis. Nineteen men were on PrEP at the time of HIV diagnosis.

Rationale: Only a subset (15 of 19 on-PrEP-at-diagnosis men) had genotype data; not all individuals in the study were sequenced.

Answer: No
"""

"""
Question: 4101 

Evidence: Partner services staff were able to confirm that 18 (95%) of these men, including those with detectable resistance mutations, were successfully linked to HIV care and initiated on active antiretroviral therapy. HIV genotype data were available for 15 (79%) of the 19 men who reported being on PrEP at the time of diagnosis.

Rationale: Genotyping was performed around diagnosis before ART initiation, indicating sequences from ART-naive individuals.

Answer: Yes
"""

"""
Question: 4102 

Evidence: Nineteen men were on PrEP at the time of HIV diagnosis. Mutations conferring emtricitabine/tenofovir resistance were identified in 8 (53%) of 15 men with available genotype data.

Rationale: These individuals had prior exposure to antiretroviral drugs as PrEP (emtricitabine/tenofovir), so sequences include persons with prior ARV exposure.

Answer: Yes
"""

"""
Question: 4103 

Evidence: HIV genotype data were available for 15 (79%) of the 19 men who reported being on PrEP at the time of diagnosis. Partner services staff were able to confirm that 18 (95%) of these men were linked to care and initiated on ART.

Rationale: The paper does not report sequences from ART-experienced patients; all were genotyped at diagnosis prior to ART, so sequences from ART-experienced individuals are not reported.

Answer: No
"""

"""
Question: 4104 

Evidence: HIV genotype data were available for 15 (79%) of the 19 men who reported being on PrEP at the time of diagnosis. Partner services staff were able to confirm that 18 (95%) of these men were successfully linked to HIV care and initiated on active antiretroviral therapy.

Rationale: Genotyping was performed before ART initiation in these newly diagnosed individuals, so the number of ART-naive individuals with sequences is 15.

Answer: 15
"""

"""
Question: 4105 

Evidence: Partner services staff were able to confirm that 18 (95%) of these men, including those with detectable resistance mutations, were successfully linked to HIV care and initiated on active antiretroviral therapy. The study collected information on demographics, sexual behavior, substance use, and history of PrEP use before HIV diagnosis.

Rationale: Detailed ART histories or regimens are not provided for all individuals; only linkage and initiation are mentioned.

Answer: No
"""

"""
Question: 4201 

Evidence: HIV genotype data were available for 15 (79%) of the 19 men who reported being on PrEP at the time of diagnosis. The remaining 8 cases (53%) had 1 or more nucleoside reverse transcriptase inhibitor resistance mutations.

Rationale: The paper does not estimate the prevalence of transmitted drug resistance in the broader newly diagnosed population; it only summarizes mutations among a small subset.

Answer: No
"""

"""
Question: 4202 

Evidence: HIV genotype data were available for 15 (79%) of the 19 men who reported being on PrEP at the time of diagnosis. The remaining 8 cases (53%) had 1 or more nucleoside reverse transcriptase inhibitor resistance mutations.

Rationale: The paper does not present prevalence estimates of pretreatment drug resistance for the cohort; it reports only counts within the small subset.

Answer: No
"""

"""
Question: 4301 

Evidence: Mutations conferring emtricitabine/tenofovir resistance were identified in 8 (53%) of 15 men with available genotype data. High-level tenofovir resistance was detected for 3 cases.

Rationale: The drugs referenced (emtricitabine and tenofovir) are NRTIs used for PrEP; no other drug classes are specified.

Answer: NRTIs (emtricitabine, tenofovir) via PrEP
"""

"""
Question: 4302 

Evidence: Mutations conferring emtricitabine/tenofovir resistance were identified in 8 (53%) of 15 men with available genotype data. Partner services staff were able to confirm that 18 (95%) of these men were successfully linked to HIV care and initiated on active antiretroviral therapy.

Rationale: There is no mention of integrase inhibitors anywhere in the paper.

Answer: No
"""

"""
Question: 4303 

Evidence: Mutations conferring emtricitabine/tenofovir resistance were identified in 8 (53%) of 15 men with available genotype data. Partner services staff were able to confirm that 18 (95%) of these men were successfully linked to HIV care and initiated on active antiretroviral therapy.

Rationale: There is no mention of protease inhibitors anywhere in the paper.

Answer: No
"""

"""
Question: 4304 

Evidence: Partner services staff were able to confirm that 18 (95%) of these men were successfully linked to HIV care and initiated on active antiretroviral therapy. The study does not describe specific ART regimens.

Rationale: Specific ART regimens are not reported; therefore it is not possible to determine whether all individuals received the same regimen.

Answer: NA
"""

"""
Question: 4305 

Evidence: The study does not describe specific ART regimens. Partner services staff were able to confirm that 18 (95%) of these men were successfully linked to HIV care and initiated on active antiretroviral therapy.

Rationale: There is no information about integrase inhibitor exposure; INSTI-naïve status cannot be determined.

Answer: NA
"""

"""
Question: 4403 

Evidence: The study does not describe specific ART regimens. Partner services staff were able to confirm that 18 (95%) of these men were successfully linked to HIV care and initiated on active antiretroviral therapy.

Rationale: The number of ART regimens per individual is not reported.

Answer: NA
"""

"""
Question: 4404 

Evidence: The study does not describe specific ART regimens. Partner services staff were able to confirm that 18 (95%) of these men were successfully linked to HIV care and initiated on active antiretroviral therapy.

Rationale: There is no data on numbers of regimens per person.

Answer: NA
"""

"""
Question: 4405 

Evidence: The study does not describe specific ART regimens. Partner services staff were able to confirm that 18 (95%) of these men were successfully linked to HIV care and initiated on active antiretroviral therapy.

Rationale: Without regimen details, it is impossible to determine whether all received the same number of regimens.

Answer: NA
"""

"""
Question: 4406 

Evidence: The study does not describe specific ART regimens. Partner services staff were able to confirm that 18 (95%) of these men were successfully linked to HIV care and initiated on active antiretroviral therapy.

Rationale: The paper does not state whether individuals received exactly one ART regimen.

Answer: NA
"""

"""
Question: 4501 

Evidence: The study does not describe specific ART regimens. Partner services staff were able to confirm that 18 (95%) of these men were successfully linked to HIV care and initiated on active antiretroviral therapy.

Rationale: There is no mention of dolutegravir usage.

Answer: NA
"""

"""
Question: 4502 

Evidence: The study does not describe specific ART regimens. Partner services staff were able to confirm that 18 (95%) of these men were successfully linked to HIV care and initiated on active antiretroviral therapy.

Rationale: There is no mention of darunavir usage.

Answer: NA
"""

"""
Question: 5101 

Evidence: Wild-type virus was identified in 7 cases (47%). The remaining 8 cases (53%) had 1 or more nucleoside reverse transcriptase inhibitor resistance mutations.

Rationale: Among the 15 genotyped individuals, 8 had at least one resistance mutation.

Answer: 8
"""

"""
Question: 5102 

Evidence: HIV genotype data were available for 15 (79%) of the 19 men who reported being on PrEP at the time of diagnosis. The paper reports only nucleoside reverse transcriptase inhibitor resistance mutations.

Rationale: Integrase resistance mutations are not reported; the number with INSTI resistance cannot be determined.

Answer: NA
"""

"""
Question: 5103 

Evidence: High-level tenofovir resistance was detected for 3 cases: 1 with K65R/M184V and 2 with A62V/K65R/M184V mutations. The remaining 8 cases (53%) had 1 or more nucleoside reverse transcriptase inhibitor resistance mutations.

Rationale: The text explicitly states that 3 cases had high-level tenofovir resistance.

Answer: 3
"""

"""
Question: 5104 

Evidence: The paper reports only nucleoside reverse transcriptase inhibitor resistance mutations (e.g., M184V, K65R). There is no mention of integrase inhibitor resistance mutations.

Rationale: Since no INSTI resistance mutations are reported, none can be listed.

Answer: NA
"""

"""
Question: 6101 

Evidence: HIV genotype data were available for 15 (79%) of the 19 men who reported being on PrEP at the time of diagnosis. The study reports no laboratory phenotypic susceptibility testing.

Rationale: Only genotypic resistance data are presented; no phenotypic method is described.

Answer: NA
"""

"""
Question: 6102 

Evidence: The study reports genotypic mutations and resistance patterns but does not present in vitro susceptibility measurements. There is no mention of IC50 or IC90 values.

Rationale: No inhibitory concentration values are provided.

Answer: No
"""

"""
Question: 6103 

Evidence: The study does not present phenotypic susceptibility testing. There is no mention of IC50 fold-change data.

Rationale: Without phenotypic assays, no fold-change values are reported.

Answer: No
"""

"""
Question: 6104 

Evidence: The paper reports only genotypic results (e.g., M184V, K65R) and does not describe phenotypic assays. There is no description of a phenotypic susceptibility platform.

Rationale: No phenotypic assay is used or named.

Answer: NA
"""

"""
Question: 6105 

Evidence: The paper focuses on PrEP use history and genotypic resistance findings. There is no mention of replication capacity measurements.

Rationale: Replication capacity data are not reported.

Answer: No
"""

"""
Question: 6106 

Evidence: The study does not include phenotypic susceptibility testing. The only drugs referenced in the context of resistance are emtricitabine and tenofovir.

Rationale: Since no phenotypic testing was conducted, no drugs were tested phenotypically.

Answer: NA
"""

"""
Question: 7101 

Evidence: These activities were conducted as part of a public health PrEP program evaluation and therefore were not considered human subjects research. We used population-based HIV partner services data to evaluate trends.

Rationale: The study does not involve constructing site-directed mutant isolates; it analyzes clinical genotypes.

Answer: No
"""

"""
Question: 7102 

Evidence: We used population-based HIV partner services data to evaluate trends in prior or ineffective PrEP use. The study does not describe laboratory in vitro passage experiments.

Rationale: No isolates result from in vitro passage; only clinical samples are discussed.

Answer: No
"""